Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval is backed by data showing deep, durable responses and manageable tolerability
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Subscribe To Our Newsletter & Stay Updated
